Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Factors Influencing Bioavailability: First-Pass Elimination

Factors Influencing Bioavailability: First-Pass Elimination

When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...

First Pass Effect

First Pass Effect

Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...

Factors Influencing Drug Absorption: Presystemic Elimination

Factors Influencing Drug Absorption: Presystemic Elimination

The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...

Hepatic Drug Excretion: Influencing Factors

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Modification of albendazole pharmacokinetics by menbutone administration in calves.

Frontiers in veterinary science·2026

Same author

Determination of Gentamicin: Development and Validation of a Sensitive UPLC-MS/MS Assay According to the European Medicines Agency Guideline.

Antibiotics (Basel, Switzerland)·2026

Same author

Intraosseous Tunneling and Ligamentum Teres Ligamentodesis "Teretization" to Enhance Stability in Congenital Hip Dislocation Surgery: Surgical Technique and Mid-Term Outcomes.

Journal of pediatric orthopedics·2025

Same author

Long-term Progress of Functional Independence of Patients With Prolonged Disorders of Consciousness Who Emerge From the Minimally Conscious State.

Archives of physical medicine and rehabilitation·2025

Same author

Differences in immunogenicity to zoster recombinant vaccine in IMID patients undergoing treatment with non-selective or selective JAK-i.

Rheumatology (Oxford, England)·2025

Same author

Pet cancer cases and patterns of treatment at a Spanish veterinary teaching hospital: a retrospective study from 2015 to 2024.

Frontiers in veterinary science·2025

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits.

Irma Villanueva¹, M José Diez, Juan J García

¹Pharmacology Area, Department of Pharmacology, Toxicology, Nursing and Physical Therapy, Veterinary Faculty, University of Leon, 24071 León, Spain.

American Journal of Veterinary Research

|November 5, 2003

Summary

This summary is machine-generated.

Levamisole exhibits low hepatic extraction in rabbits, indicating minimal first-pass metabolism. This study assessed levamisole disposition and pharmacokinetics following intravenous and jejunal administration.

More Related Videos

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Published on: March 27, 2021

X-ray Visualization of Intraductal Ethanol-based Ablative Infusion for Prevention of Breast Cancer in Rabbit Models

X-ray Visualization of Intraductal Ethanol-based Ablative Infusion for Prevention of Breast Cancer in Rabbit Models

Published on: September 12, 2025

Related Experiment Videos

Last Updated: Jul 5, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

Published on: March 27, 2021

X-ray Visualization of Intraductal Ethanol-based Ablative Infusion for Prevention of Breast Cancer in Rabbit Models

X-ray Visualization of Intraductal Ethanol-based Ablative Infusion for Prevention of Breast Cancer in Rabbit Models

Published on: September 12, 2025

Area of Science:

Pharmacokinetics and Drug Metabolism
Veterinary Pharmacology
Hepatology

Background:

Levamisole is an anthelmintic and immunomodulatory drug.
Understanding first-pass hepatic metabolism is crucial for drug disposition.
Rabbit models are frequently used to study drug pharmacokinetics.

Purpose of the Study:

To quantify the contribution of first-pass hepatic metabolism of levamisole.
To evaluate levamisole disposition in rabbits following different administration routes.

Main Methods:

Thirty male New Zealand White rabbits were used.
Levamisole was administered intravenously (marginal ear vein) and intraportally (jejunal vein) at 12.5, 16, and 20 mg/kg.
Plasma levamisole concentrations were measured over 240 minutes using high-performance liquid chromatography.

Main Results:

No significant differences in pharmacokinetic parameters were observed between compartmental and noncompartmental analyses.
The mean hepatic extraction ratio for levamisole was low, ranging from -0.044 to 0.081.
Pharmacokinetic parameters such as volume of distribution, clearance, and half-life were determined for both administration routes.

Conclusions:

Levamisole undergoes a low degree of first-pass hepatic extraction in rabbits.
Hepatic metabolism has a minimal impact on levamisole disposition in this species.
The findings contribute to understanding levamisole's pharmacokinetic profile.